Advertisement
Screener

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2.0 / 5 stars · 19/47 Roast Me

PROVECTUS BIOPHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 120.00 thousand shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-05-14

  • PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 120.00K shares.
  • PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2014-12-31 was 0.00 shares.
  • PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2012-09-30 was 0.00 shares.
  • PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2012-06-30 was 0.00 shares.
  • PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 365.24K shares, a 99.27% decline from fiscal 2024.
  • PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 50.32M shares.
  • PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 2.52M shares.
  • PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 0.00 shares, a 100.00% decline from fiscal 2015.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, GrossShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month
2026-03-31120.00K shares
10-Q · filed 2026-05-14
2025-12-31365.24K shares
10-K · filed 2026-03-26
2024-12-3150.32M shares
10-K · filed 2025-03-28
2024-12-0250.32M shares
10-K · filed 2026-03-26
2020-12-312.52M shares
10-K · filed 2022-03-29
2016-12-310.00 shares
10-K · filed 2017-03-31
2015-12-311.75M shares
10-K · filed 2016-03-30
2014-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
150.00K shares
10-K · filed 2015-03-12
2014-09-30150.00K shares
10-Q · filed 2014-11-06
2014-07-29150.00K shares
10-K · filed 2016-03-30
2013-09-30250.00K shares
10-Q · filed 2013-11-12
2013-08-19250.00K shares
10-Q · filed 2014-11-06
2012-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08
0.00 shares
derived: sum of 2 quarters · filed 2012-11-08
250.00K shares
10-Q · filed 2012-11-08
2012-06-30200.00K shares
10-Q · filed 2012-08-08
0.00 shares
10-Q · filed 2012-08-08
250.00K shares
10-Q · filed 2012-08-08
2012-05-3150.00K shares
10-Q · filed 2012-08-08